Status: Recruiting
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Lanyi Therapeutics Co., Ltd.Updated: May 14, 2026Locations: 2
Eligibility criteria
Male or female subjects aged ≥18 years. [+13]
History of allogeneic bone marrow transplantation. [+20]